Aura Biosciences (AURA) Cash & Current Investments (2020 - 2026)

Aura Biosciences has reported Cash & Current Investments for 7 years, with the latest figure at $84.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 121.82% year-over-year to $84.8 million; the trailing twelve-month figure through Mar 2026 stood at $84.8 million (up 121.82% YoY), and the FY2025 full-year result was $59.5 million, up 87.79% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $84.8 million, up from $59.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $107.4 million in Q2 2025, with the low at $19000.0 in Q4 2023.
• Historically, Cash & Current Investments has averaged $32.4 million across 5 years, with a median of $30.1 million in 2024.
• The largest YoY upside for Cash & Current Investments was 305450.0% in 2022 against a maximum downside of 99.99% in 2022.
• Aura Biosciences' Cash & Current Investments stood at $20000.0 in 2022, then fell by 5.0% to $19000.0 in 2023, then soared by 166705.26% to $31.7 million in 2024, then jumped by 87.79% to $59.5 million in 2025, then jumped by 42.47% to $84.8 million in 2026.
• The last three Cash & Current Investments figures came in at $84.8 million (Q1 2026), $59.5 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.